IRAK4-targeted PROTACs can eliminate both enzymatic and non-enzymatic functions of IRAK4, and due to better cellular penetration in immune cells compared to solid tumors, they represent a promising new strategy for autoimmune disease therapy. The gene discussed is IRAK4; the disease is autoimmune disease.